Mala Gaonkar, founder of SurgoCap Partners, outlines her investment philosophy centered on identifying a small number of high-quality businesses with long-duration competitive moats.
The firm's strategy focuses on the intersection of technology with non-tech sectors, particularly how established technologies can create new disruptions in industries like healthcare, finance, and automotive.
Gaonkar identifies significant opportunities in AI, emphasizing the recurring, annuity-like revenue potential of AI inference over the more cyclical nature of AI training, and highlights its transformative impact on medical imaging and robotic surgery.
A core tenet of the firm is a disciplined, data-driven process that mitigates cognitive biases, combined with a small, collaborative team structure to foster creative, cross-sector idea generation.
12 quotes
Concerns Raised
Execution risk in technology companies deploying large amounts of capital
The danger of emotional decision-making and over-excitement in investing
Businesses with weak balance sheets and excessive leverage
The 'spiky' and less predictable nature of AI training revenue cycles
Opportunities Identified
AI inference as a recurring, annuity-like revenue stream
Application-Specific Integrated Circuits (ASICs) that create long-duration moats in the semiconductor space
AI-driven improvements in medical imaging and robotic surgery
Proprietary real-time data providers whose workflows are difficult for AI to disrupt
Identifying how established technologies can disrupt non-tech industries